Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: Consideration of multiple binding sites in in vitro assay design

Drug Metabolism and Disposition

Volumn 37, Issue 3, 2009, Pages 560-570

  Giri, Nagdeep ^a   Agarwal, Sagar ^a   Shaik, Naveed ^a   Pan, Guoyu ^a   Chen, Ying ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 ISOBUTYL 9 METHOXY 1,4 DIOXO 1,2,3,4,6,7,12,12A OCTAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOL 3 YL)PROPIONIC ACID TERT BUTYL ESTER; ABACAVIR; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; IMATINIB; KO 143; MYCOTOXIN; NELFINAVIR; PLURONIC P 85; POLOXAMER; PRAZOSIN; UNCLASSIFIED DRUG; ZIDOVUDINE; ZOSUQUIDAR;

ANIMAL CELL; ARTICLE; DRUG BINDING SITE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; IN VITRO STUDY; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPORT KINETICS;

ACRIDINES; ADENOSINE; ANIMALS; BINDING SITES; CELL LINE; DOGS; NELFINAVIR; NEOPLASM PROTEINS; POLOXAMER; PROTEIN BINDING; TETRAHYDROISOQUINOLINES;

MURINAE;

EID: 61449121173     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022046     Document Type: Article

References (40)

1. Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H, and Bentz J (2006) P-glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKH cells has more than one efflux pathway with cooperative binding sites. Biochemistry 45:15505-15519.
2. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, and Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425.
3. Ambudkar SV, Kim IW, and Sauna ZE (2006) The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27:392-400.
4. Batrakova EV, Li S, Alakhov VY, Elmquist WF, Miller DW, and Kabanov AV (2003) Sensitization of cells overexpressing multidrug-resistant proteins by Pluronic P85. Pharm Res 20:1581-1590.
5. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, and Kabanov AV (2001a) Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 299:483-493.
6. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, and Elmquist WF (2001b) Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 296:551-557.
7. Bhatia A, Schäfer HJ, and Hrycyna CA (2005) Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry 44:10893-10904.
8. Braun A, Hammerle S, Suda K, Rothen-Rutishauser B, Gunthert M, Kramer SD, and Wunderli-Allenspach H (2000) Cell cultures as tools in biopharmacy. Eur J Pharm Sci 11 (Suppl 2):S51-S60.
9. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrpl (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582.
10. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, et al. (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21: 1267-1275.
11. Burger H, van Toi H, Boersma AW, Brok M, Wiemer EA, Stoter G, and Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940-2942.
12. Clark R, Kerr ID, and Callaghan R (2006) Multiple drug binding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 149:506-515.
13. Dai H, Marbach P, Lemaire M, Hayes M, and Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092.
14. Ejendal KF and Hrycyna CA (2005) Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol 67:902-911.
15. Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D Jr, and Glue PW (2008) Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy 28:42-50.
16. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, and Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374-383.
17. Gupta A, Zhang Y, Unadkat JD, and Mao Q (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334-341.
18. Hazai E and Bikádi Z (2008) Homology modeling of breast cancer resistance protein (ABCG2). J Struct Biol 162:63-74.
19. Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, and Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90:526-536.
20. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
21. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRPl, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
22. Loo TW, Bartlett MC, and Clarke DM (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278:39706-39710.
23. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
24. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
25. Matsson P, Englund G, Ahlin G, Bergström CA, Norinder U, and Artursson P (2007) A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 323:19-30.
26. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, and Prieto JG (2006) Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
27. Muenster U, Grieshop B, Ickenroth K, and Gnoth MJ (2008) Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 25:2320-2326.
28. Pan G, Giri N, and Elmquist WF (2007) Abcg2/Bcrpl mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 35:1165-1173.
29. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, and Polli JW (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
30. Senior AE and Bhagat S (1998) P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites. Biochemistry 37:831-836.
31. Shaik N, Giri N, Pan G, and Elmquist WF (2007) P-glycoprotein-mediated active efflux of the anti-HIV 1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 35:2076-2085.
32. Shaik N, Pan G, and Elmquist WF (2008) Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci 97:5421-5433.
33. Staud F and Pavek P (2005) Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37:720-725.
34. Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, and Schuetz JD (2007) Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67:6965-6972.
35. Tang F, Horie K, and Borchardt RT (2002) Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:765-772.
36. Warnke D, Barreto J, and Temesgen Z (2007) Antiretroviral drugs. J Clin Pharmacol 47:1570-1579.
37. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, and Efferth T (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238-245.
38. Xia CQ, Liu N, Miwa GT, and Gan LS (2007) Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos 35:576-582.
39. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, and Sugiyama Y (2007) Effect of excipients on breast cancer resistance protein substrate uptake activity. J Control Release 124:1-5.
40. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, and Ware JA (2006) Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55-61.